DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1494)

Amyloidosis | Landscape & Forecast | Disease Landscape & Forecast

Amyloidosis | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Amyloidosis refers to the disruption and damage to organs and tissues due to deposits of abnormal, insoluble amyloid fibrils, which are formed by the accumulation of misfolded proteins. Amyloid immunoglobulin light chain (AL), amyloid A (AA), and amyloid transthyretin (ATTR) are three major subtypes of amyloidosis, termed after the corresponding protein precursor. Treatment options for multiple myeloma are used off-label for AL amyloidosis. In 2011, the EMA approved the TTR stabilizer tafamidas—Pfizer’s Vyndaquel—for ATTR-familial amyloid polyneuropathy; it is the only drug ever to gain approval for any subtype of amyloidosis. Thanks to the growing knowledge of the pathogenesis of amyloidosis, several agents with novel mechanisms of action are in late-stage development and likely to reach the market in the near term.

  • Pub Date: December 2016
  • Author(s): Jing Wu

Request report

Related reports:
You may also be interested in: